At a glance
ClinicalIndex Comparison Record- ✓Presentation with SVT due to AVRT or AVNRT
- ✓Age 4 months or less at presentation
- ✓No major structural heart disease (PFO and PDA allowable)
- ✕Structural heart disease other than PFO or PDA
- ✕Persistent abnormal cardiac function (shortening fraction <28%)
- ✕Pre-excitation (Wolff Parkinson White syndrome)
- ✕Permanent junctional reciprocating tachycardia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia
In Brief
A Phase 3 clinical trial evaluating Digoxin and Propranolol for Supraventricular Tachycardia. Completed, enrolled 72 participants across 14 sites in 2 countries.
Detailed Summary
This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.